biotech · Acute Myeloid Leukemia (AML) · Ovarian Cancer · STRO
SUTRO BIOPHARMA
SUTRO BIOPHARMA, INC.
SUTRO BIOPHARMA patent portfolio — 34 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2003
- Employees
- 212
- Programs
- 10
- Drugs
- 21
- Patents
- 34
SUTRO BIOPHARMA patents
34 pharmaceutical patents indexed for SUTRO BIOPHARMA. 0 expire within 24 months.
SUTRO BIOPHARMA has 34 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12427201
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
granted -
US 12398197
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
granted -
US 12351850
Methods of producing full-length antibodies using E. coli
granted -
US 12269801
Modified amino acids
granted -
US 12252552
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
granted -
US 12226490
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class
granted -
US 12144869
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
granted -
US 12071477
Anti-folate receptor alpha antibody conjugated with hemiasterlins
granted -
US 11993658
Anti-BCMA antibodies and treatment methods
granted -
US 11958909
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
granted -
US 11866515
Hemiasterlin derivatives for conjugation and therapy
granted -
US 11744876
Immunomodulator antibody drug conjugates and uses thereof
granted -
US 11708413
Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
granted -
US 11548852
Modified amino acids
granted -
US 11344626
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
granted -
US 11098131
Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies
granted -
US 11098107
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
granted -
US 11014983
Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
granted -
US 10975150
Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies
granted -
US 10844090
Hemiasterlin derivatives for conjugation and therapy
granted -
US 10822414
Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
granted -
US 10730837
Modified amino acids
granted -
US 10669347
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
granted -
US 10596270
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
granted -
US 10501558
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
granted -
US 10442789
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
granted -
US 10112900
Modified amino acids
granted -
US 9994527
Modified amino acids
granted -
US 9938516
Non-natural amino acid tRNA synthetases for para-methylazido-L-phenylalanine
granted -
US 9840493
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
granted -
US 9764039
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
granted -
US 9738724
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
granted -
US 9732161
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
granted -
US 9682934
Modified amino acids
granted
Frequently asked questions
How many patents does SUTRO BIOPHARMA have?
34 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do SUTRO BIOPHARMA patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.